Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2006-08-22
2006-08-22
Sheikh, Humera N. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S451000, C424S456000, C424S464000, C424S465000, C424S468000, C424S474000, C424S484000, C424S489000
Reexamination Certificate
active
07094427
ABSTRACT:
The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.
REFERENCES:
patent: 3891696 (1975-06-01), Bodor et al.
patent: 4021555 (1977-05-01), Seyfried et al.
patent: 4160020 (1979-07-01), Ayer et al.
patent: 4424235 (1984-01-01), Sheth et al.
patent: 4832957 (1989-05-01), Dempski et al.
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4900755 (1990-02-01), Dempski et al.
patent: 4963590 (1990-10-01), Backstrom et al.
patent: 5112861 (1992-05-01), Backstrom et al.
patent: 5135950 (1992-08-01), Pippuri et al.
patent: 5188840 (1993-02-01), Iida et al.
patent: 5652271 (1997-07-01), Harris et al.
patent: 5738874 (1998-04-01), Conte et al.
patent: 5945424 (1999-08-01), Schmidt
patent: 6238699 (2001-05-01), Rubin
patent: 6294200 (2001-09-01), Conte et al.
patent: 6500867 (2002-12-01), Virkki et al.
patent: 6797732 (2004-09-01), Virkki et al.
patent: WO 95/01781 (1995-01-01), None
patent: 99/17745 (1999-04-01), None
patent: WO 99/17745 (1999-04-01), None
Grahnén et al., “Comparative Multiple-Dose Pharmacokinetics of Controlled-Release Levodopa Products,” Eur. Neurol. 1992:32; pp. 343-348.
Stocchi et al., “Comparison Between a Fast and a Slow Release Preparation of Levodopa and a Combination of the Two: A Clinical and Pharmacokinetic Study,” Clinical Neuropharmacology, vol. 17, No. 1, pp. 38-44.
Stocchi et al., “Clinical Implications of Sustained Dopaminergic Stimulation,” Clinical Neuropharmacology, vol. 17, Suppl. 2, pp. S7-S13.
Stocchi et al., “Clinical Efficacy of Single Morning Doses of Different Levodopa Formulations,” Clinical Neuropharmacology, vol. 17, Suppl. 3, pp. S16-S20.
Harder et al., “Concentration-Effect Relationship of Levodopa in Patients with Parkinson's Disease After Oral Administration of an Immediate Release and a Controlled Release Formulation,” Br. J. Clin. Pharmac. 1995; 39: pp. 39-44.
Fassihi et al., “Multiple-Layer, Direct-Compression, Controlled-Release System: In Vitro and In Vivo Evaluation,” Journal of Pharmaceutical Sciences, vol. 82, No. 7, Jul. 1993, pp. 750-754.
Ghika et al., “Clinical Efficacy and Tolerability of a New Levodopa/Benserazide Dual-Release Formulation in Parkinsonian Patients,” Clinical Neuropharmacology, vol. 20, No. 2, pp. 130-139.
Gasser et al., “Comparative Single- and Multiple-Dose Pharmacokinetics of Levodopa and 3-O-Methyldopa Following a New Dual-Release and a Conventional Slow-Release Formulation of Levodopa and Benserazide in Healthy Subjects,” European Journal of Pharmaceutics and Biopharmaceutics 46 (1998) pp. 223-228.
Descombes et al., “Dual-Release Formulation, A Novel Principle in L-dopa Treatment of Parkinson's Disease,” Neurology 56, May (1 of 2) 2001, pp. 1239-1242.
Roger Kurlan et al., “Duodenal and Gastric Delivery of Levodopa in Parkinsonism,” American Neurological Association, 1988.
John G. Nutt et al., “Review, Pharmacokinetics of Levodopa,” Clinical Neuropharmacology, vol. 7, No. 1, pp. 35-49, 1984 Raven Press, New York.
R. Kurlan, et al., “Erratic gatric emptying of levodopa may cause “random” fluctuations of parkinsonianmobility,” Neurology, Mar. 1988.
Han Chien-Hsuan
Hsu Ann F.
Hsu Larry
Impax Laboratories, Inc.
Sheikh Humera N.
LandOfFree
Combination immediate release controlled release... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination immediate release controlled release..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination immediate release controlled release... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3640965